The "Investigation Report on Chinese Valsartan Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The growing economy has greatly changed the lifestyle and diet of Chinese people and led to the increasing incidence of hypertension in China. According to population size and structure, China has over 300 million hypertensive patients, over 1/3 of the global total. However, China has a wide gap with developed countries on hypertension control rate.
According to research, the sales value of Valsartan was about CNY 537 million in 2017, a slight decrease over 2016. The sales volume increased while the average price fell, which doesn't mean shrinking market demand.
There are many Valsartan manufacturers in China while the concentration ratio is high. In 2017, over 90% market share by sales value was captured by Beijing Novartis Pharma Co., Ltd., Lunan Better Pharmaceutical Co., Ltd., Novartis and Changzhou Siyao Pharmaceutical Co., Ltd.
The Valsartan (trade name: Diovan) produced by Beijing Novartis Pharma Co., Ltd. took up over 85% of the Chinese market, and the domestic enterprises also gained some market share by price advantage.
Many domestic pharmaceutical enterprises expect to scrabble for market shares from Novartis by advantage of lower prices. For example, in June 2018, Zhejiang Huahai Pharmaceutical Co., Ltd. obtained the production permit for Valsartan tablets (40mg, 80mg and 160mg) from CFDA.
It is estimated that the incidence of hypertension and the demand for Valsartan will continue to grow in China in the coming years.
For more information about this report visit https://www.researchandmarkets.com/research/jszmlp/valsartan?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005625/en/